For example, the finding that PARP1 is required to recruit certain RBPs to DNA damage sites [59–61] implies that PARP1 inhibitors may be used to inhibit the RBP-dependent DNA-repair pathway for cancer treatment. The gene discussed is PARP1; the disease is cancer.